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Metformin is currently the first-line drug treatment for type 2 diabetes. Besides its glucose-lowering effect,
there is interest in actions of the drug of potential relevance to cardiovascular diseases and cancer. However,
the underlying mechanisms of action remain elusive. Convincing data place energy metabolism at the center
of metformin’s mechanism of action in diabetes and may also be of importance in cardiovascular diseases
and cancer. Metformin-induced activation of the energy-sensor AMPK is well documented, but may not ac-
count for all actions of the drug. Here, we summarize current knowledge about the different AMPK-depen-
dent and AMPK-independent mechanisms underlying metformin action.Introduction
Metformin has been an important drug for treatment of type 2
diabetes (T2D) for decades. It is themost widely used oral antihy-
perglycemic agent and is currently recommended as first line
therapy for all newly diagnosed T2D patients (American Diabetes
Association, 2014). Metformin (N, N-dimethylbiguanide) belongs
to the biguanide class of antidiabetic drugs (containing two linked
guanidine rings) originally derived from galegine (isoamylene
guanidine), a guanidine derivative found in the French lilacGalega
officinalis. Among the three biguanides developed for diabetes
therapy, metformin has a superior safety profile, and it is well
tolerated. Two other biguanides, phenformin and buformin,
were withdrawn in the early 1970’s due to risk of lactic acidosis
and increased cardiac mortality. The incidence of lactic acidosis
with metformin at therapeutic doses is rare (less than three cases
per 100.000 patient-years) and not greater than with non-metfor-
min therapies. Metformin has been used widely in the treatment
of T2D for over 50 years and has been found to be safe and effi-
cacious both as monotherapy and in combination with other oral
antidiabetic agents and insulin. It offers the major clinical advan-
tage of not inducing hypoglycemia or weight gain and amelio-
rates hyperglycemia with remarkable cardiovascular safety.
Besides its use in T2D, there is interest in the use of metformin
for the treatment of polycystic ovary disease, diabetic nephropa-
thy, and gestational diabetes (Viollet et al., 2012). The drug also
has the advantage of counteracting the cardiovascular complica-
tions associated with diabetes as reported in a large cohort of in-
dividuals from the United Kingdom Prospective Diabetic Study
(UKPDS) (1998). Another possible benefit for metformin use is
the association with decreased cancer risk and improved cancer
prognosis (Pollak, 2012b; Viollet et al., 2012). Althoughmetformin
has been used in Europe for treatment of hyperglycemia since
1957 (and in the USA since FDA approval in 1994), the exact
molecular mechanisms of its therapeutic action remain obscure.
In this review, we summarize what is currently known about these
molecular mechanisms in the context of classic use for T2D and
also for possible novel areas of therapeutic application.Pharmacokinetics and Pharmacogenomics
Pharmacokinetics of Metformin
The optimal oral metformin dose for many diabetic patients is2
g/day. After a single oral dose, metformin is rapidly distributed to
many tissues following partial absorption by the small intestine,
but the luminal concentration in the gastrointestinal tract remains
high. The peak plasma concentration occurs in 3 hr (increasing
from 1.0 to 1.6 mg/ml [about 6 to 10 mM] after a 0.5 g dose and
to3 mg/ml [about 18 mM] after a 1.5 g dose) with a mean plasma
half-life of about 20 hr (Tucker et al., 1981).When the humanmet-
formin dose of 20 mg/kg/day orally is translated to the mouse
equivalent dose of 250 mg/kg/day, according to the normaliza-
tion to body surface area, murine plasma levels of metformin of
up to 1.7 mg/ml (about 10 mM) are achieved (Memmott et al.,
2010). This is in the range achieved when conventional antidia-
betic doses are used in humans (Tucker et al., 1981). Bio-
distribution studies in mice using 14C-labeled metformin showed
accumulationmainly in the gastrointestinal tract, kidney, and liver
(Wilcock and Bailey, 1994). It is important to note that being sup-
plied directly by blood coming from the portal vein, the liver may
contain a concentration of orally administered metformin sub-
stantially higher than in the general circulation and other organs
(Wilcock and Bailey, 1994). Metformin liver concentrations of
greater than 180 mmol/kgwetweight and 250 mmol/kgwetweight
in normal and diabetic rodents, respectively, can be achieved af-
ter a single dose of 50 mg/kg (Wilcock and Bailey, 1994).
Cellular Uptake of Metformin
Metformin is an unusually hydrophilic drug that mostly exists in a
positively charged protonated form under physiological condi-
tions. These physicochemical propertiesmake rapid and passive
diffusion through cell membranes unlikely. Indeed, transport of
metformin involves an active uptake process via solute carrier
organic transporters. The intestinal absorption of metformin
is primarily mediated by the plasma membrane monoamine
transporter (PMAT, SLC29A4 gene), which is localized on the
luminal side of enterocytes. Organic cation transporter 1 (Oct1,
SLC22A1 gene) is expressed on the basolateral membrane ofCell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc. 953
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min into the interstitial fluid (Gong et al., 2012). The primary medi-
ator of hepatic metformin uptake is OCT1 and possibly OCT3
(SLC22A3 gene), expressed at the basolateral membrane of he-
patocytes (Gong et al., 2012). The clearance of metformin is
dependent on renal elimination, as metformin does not undergo
relevant biotransformation in the liver or biliary excretion. In the
kidney, metformin is taken up into renal epithelial cells by
OCT2 (SLC22A2gene), expressed on the basolateralmembrane,
and excreted into the urine via multidrug and toxin extrusion 1
and 2 (MATE1 gene SLC47A1 and MATE2 gene SLC47A2).
Pharmacogenomics of Metformin
Considerable interindividual heterogeneity in clinical efficacy
and the pharmacokinetic disposition of metformin has been
reported in the treatment of diabetic patients. This may be
explained by variability in genetic polymorphisms of cation trans-
porters. It was first reported that individuals carrying polymor-
phisms of the OCT1 gene SLC22A1 display an impaired effect
of metformin in lowering blood glucose levels, consistent with
the great reduction of hepatic metformin uptake observed in
OCT1/ mice (Shu et al., 2007). However, these results have
not been confirmed in the long-term follow-up of a large obser-
vational cohort of patients treated with metformin (Zhou et al.,
2009). Conversely, variants in the MATE1 gene SLC47A1 en-
hance the effect of metformin on glycated hemoglobin (HbA1c)
and glucose tolerance in T2D patients (Becker et al., 2009). In
MATE1/ mice, urinary excretion of metformin is significantly
decreased, suggesting that MATE1 is essential for renal clear-
ance of the drug (Tsuda et al., 2009). Among new candidate ge-
netic determinants of metformin response, single nucleotide
polymorphisms have been identified in the AMPK subunit genes,
PRKAA1, PRKAA2 and PRKAB2, and the LKB1 gene STK11
(Jablonski et al., 2010). In addition, a recent genome-wide asso-
ciation study showed association between a large locus on
chromosome 11, encompassing several genes, and glycemic
variability in response to metformin therapy (Zhou et al., 2011).
This locus includes the ataxia telangiectasia mutated (ATM)
gene, and it was suggested as the most likely candidate given
its association with insulin resistance and T2D. However, addi-
tional studies are needed to clearly delineate genetic influences
on the clinical response to metformin.
Metformin andMitochondrial Oxidative Phosphorylation
It is generally accepted that actions of metformin (and other bi-
guanides) on mitochondria underlie most of the pleiotropic ef-
fects of the drug. This emerging consensus originates from
two seminal papers published in 2000 reporting that metformin
decreases cellular respiration by a mild and specific inhibition
of the respiratory-chain complex 1 (NADH:ubiquinone oxidore-
ductase) without affecting any other steps of the mitochondrial
machinery (El-Mir et al., 2000; Owen et al., 2000). However, re-
viewing early mechanistic studies, the first observation reporting
effects of biguanide derivatives onmitochondrial oxidative phos-
phorylation (OXPHOS) comes from the pioneering work of Hol-
lunger in the 1950s that linked the increase in glycolysis induced
by this class of molecules to the inhibition of cellular respiration
(Hollunger, 1955). Later, high concentrations of various bigua-
nide derivatives were found to specifically reduce NADH but
not succinate oxidation in submitochondrial particles, assigning
the inhibitory effect of these compounds on OXPHOS to the954 Cell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc.complex 1 of the mitochondrial electron transport chain (ETC).
Thus, the concept that members of the biguanide family,
including phenformin and metformin, exert many of their actions
though modulation of mitochondrial energetics is not a recent
proposal. During the last decade, the specific inhibition of the
mitochondrial respiratory-chain complex 1 by metformin was
confirmed in many cellular models, including rat, mouse and hu-
man primary hepatocytes (El-Mir et al., 2000; Owen et al., 2000;
Stephenne et al., 2011), hepatoma, and adrenocortical carci-
noma immortalized cell lines (Guigas et al., 2004; Hirsch et al.,
2012; Kim et al., 2013), skeletal muscle homogenates (Brunmair
et al., 2004), endothelial cells (Detaille et al., 2005), pancreatic
beta cells (Hinke et al., 2007), neurons (El-Mir et al., 2008), pe-
ripheral blood mononuclear cells and platelets (Piel et al.,
2014), and more recently in cancer cells (Bridges et al., 2014;
Janzer et al., 2014; Scotland et al., 2013; Wheaton et al.,
2014). It has been reported that this transient inhibition of com-
plex 1 induces a drop in cellular energy charge, a measure of
the energetic state of the cell defined as ([ATP] + 0.5[ADP])/
([ATP] + [ADP] + [AMP]) (Foretz et al., 2010; Stephenne et al.,
2011). The resulting fall in cellular ATP concentration and an
increase in both ADP/ATP and AMP/ATP ratios activates the
AMP-activated protein kinase (AMPK), a critical energy sensor
of cellular energy homeostasis that integrates multiple signaling
networks to coordinate a wide array of compensatory, protec-
tive, and energy-sparing responses (Viollet et al., 2012).
Although the exact mechanism(s) by which metformin inhibits
complex 1 remains unknown, some studies were unable to
detect a direct effect on isolated mitochondria except at very
high concentrations, suggesting that the mitochondrial action
of the drug requires intact cells (El-Mir et al., 2000; Guigas
et al., 2004). On the other hand, it was recently reported that
metformin (and other biguanides) can directly inhibit function of
purified respiratory-chain complex 1, as well as in isolated mito-
chondria and submitochondrial particles from bovine heart
(Andrzejewski et al., 2014; Bridges et al., 2014), in line with pre-
vious data reporting similar properties using very high concen-
trations (20–100 mM) of the drug (Dykens et al., 2008; Owen
et al., 2000). However, it remains to be demonstrated if these
mechanisms operate in vivo.
It was also shown that the inhibitory effect of metformin on
complex 1was not prevented by nitric oxide (NO) synthase inhib-
itors or reactive oxygen species (ROS) scavengers (El-Mir et al.,
2000) and was independent of AMPK, at least in primary mouse
hepatocytes (Stephenne et al., 2011). Among the possible un-
derlying mechanisms, it was proposed that the positive charge
ofmetforminmight account for its accumulation within thematrix
of energized mitochondria, driven by the membrane potential
(Owen et al., 2000). In addition, its apolar hydrocarbon side-
chain would also promote its binding to hydrophobic structures,
such as the constitutive phospholipids of mitochondrial mem-
branes. Importantly, the lipophilicity of metformin, which is
mostly due to its dimethyl-substituted terminal amino group, is
much less than those of phenformin, which is more evenly
distributed along its biguanide backbone. These peculiar physi-
cochemical characteristics explain why two structurally related
biguanides affect differently the mitochondrial machinery, met-
formin being a weak but specific inhibitor of complex 1 whereas
phenformin exerting amore potent but less specific action on the
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mentioning that the inhibition of complex 1 activity by metformin
is rather mild when compared to the reference inhibitor rotenone
(El-Mir et al., 2000). Furthermore, metformin was shown to signif-
icantly reduce mitochondrial ROS production by selective inhibi-
tion of the reverse electron flow through the respiratory-chain
complex 1, whereas rotenone triggers ROS production by
increasing forward electron flow (Batandier et al., 2006). Taken
together, this suggests that their respective site of action on
one or several of the subunits constituting the respiratory-chain
complex 1 differ. Although recent studies have led to significant
improvements in the understanding of its structure-function rela-
tionships (Bridges et al., 2014), many aspects of the regulation of
mitochondrial complex 1, such as the so-called active/deactive
transition, remain incompletely understood. Further investiga-
tions are therefore still required to clarify the mechanism(s) by
which metformin modulates the respiratory-chain complex 1 in
such a unique way. Interestingly, it has been reported that direct
binding of metformin to mitochondrial copper ions might be
crucial for the metabolic effects of the drug (Logie et al., 2012).
These findings point out again the crucial involvement of mito-
chondria in the molecular mechanism of action of metformin.
Of note, not all the effects of biguanides are mediated by mito-
chondria since the glucose metabolism of erythrocytes, which
are devoid of this organelle, was shown to be significantly
affected secondary to metformin-induced change in cell mem-
brane fluidity induced by the drug (Muller et al., 1997).
Metformin and Treatment of Type 2 Diabetes
Metformin exerts its glucose-lowering effect primarily by
decreasing hepatic glucose production through suppression of
gluconeogenesis and enhancing insulin suppression of endoge-
nous glucose production and, to a lesser extent, by reducing
intestinal glucose absorption and possibly improving glucose
uptake and utilization by peripheral tissues, such as skeletal
muscle and adipose tissue (Natali and Ferrannini, 2006). Of
note, it has been reported that metformin does not improve pe-
ripheral insulin sensitivity (Natali and Ferrannini, 2006), and im-
provements in insulin sensitivity in muscle may be related to
the use of higher doses of metformin than clinically relevant.
Additionally, metformin may also improve glucose homeostasis
by interacting with the incretin axis through the action of
glucagon-like peptide 1 (GLP-1) (Maida et al., 2011; Mulherin
et al., 2011). A recent study has found evidence that metformin
and phenformin antagonize the action of the counter-regulatory
hormone glucagon to suppress hepatic glucose production
(Miller et al., 2013). Furthermore, Fullerton and colleagues
recently showed that metformin-induced improvements in insu-
lin action operate through alterations in hepatic lipid homeosta-
sis via the inhibitory phosphorylation of acetyl CoA carboxylase
(ACC) by AMPK (Fullerton et al., 2013).
Inhibition of Hepatic Gluconeogenesis
An important breakthrough in the understanding of themolecular
mechanism underlying metformin action was the demonstration
that metformin-induced AMPK activation is associated with the
inhibition of glucose production in primary hepatocytes (Zhou
et al., 2001). The role for AMPK in mediating the action of metfor-
min was initially supported by the reduction in metformin’s effect
on glucose production in primary hepatocytes treated with com-
pound C (Zhou et al., 2001), an AMPK inhibitor that is now recog-nized to be nonselective. Thereafter, it was reported that,
ablation of liver kinase B1 (LKB1, the upstream kinase that phos-
phorylates and activates AMPK) in the liver prevented the antihy-
perglycemic effects of metformin in high-fat-fed mice (Shaw
et al., 2005), also supporting the involvement of the kinase in
the inhibition of glucose production by the drug. In this study, it
was shown that LKB1/AMPK signaling controls the phosphoryla-
tion and nuclear exclusion of the transcriptional coactivator
cAMP-response element-binding protein (CREB)-regulated
transcription coactivator 2 (CRTC2, also known as TORC2)
(Shaw et al., 2005), a pivotal regulator of gluconeogenic gene
transcription in response to fasting. In addition, AMPK activation
by metformin has also been reported to be involved in the tran-
scriptional regulation of hepatic gluconeogenic enzyme genes
by different mechanisms: (i) dissociation of the CREB-CBP
(CREB-binding protein)-TORC2 transcription complex, through
the phosphorylation of the transcriptional coactivator CBP via
atypical protein kinase C i/l (He et al., 2009), (ii) increased
expression of the orphan nuclear receptor small heterodimer
partner (Lee et al., 2010), and (iii) induction of SIRT1-mediated
CRTC2 deacetylation (Caton et al., 2010). However, the impact
of reduction in gluconeogenic gene expression in metformin
action has been recently disputed. Forced increase in gluconeo-
genic enzymes expression did not counteract the metformin-
induced reduction in glucose output (Foretz et al., 2010), this
being in line with the emerging concept that transcriptional
expression of PEPCK and G6Pase only weakly influences hepat-
ic glucose output in patients with T2D (Samuel et al., 2009).
Over the last years, controversy has arisen concerning the
involvement of AMPK in the therapeutic effects of metformin
on hepatic glucose production. Indeed, although metformin ac-
tivates AMPK, this may not explain all of the therapeutic effects
of the drug. Recent work in liver and primary hepatocytes from
knockout models for both AMPKa1/a2 catalytic subunits and
the upstream activating kinase LKB1 reveal that neither AMPK
nor LKB1 are essential for metformin inhibition of hepatic glu-
cose production (Foretz et al., 2010). However, a new report
challenges these results and now shows that low concentrations
of metformin suppress glucose production via AMPK activation
independently of an increase in the AMP/ATP ratio (Cao et al.,
2014). A central question raised by this work is how metformin
activates AMPK without affecting energy charge. As described
above, there is a consensus that metformin activates AMPK indi-
rectly, secondary to the inhibition of the mitochondrial respira-
tory-chain complex 1, leading to ATP depletion and an increase
in AMP levels (Hawley et al., 2010). In addition, it has been sug-
gested that perturbation of intracellular ATP levels, but not
AMPK activation per se or inhibition of gluconeogenic gene
expression, constitutes the critical factor underlying the effects
of metformin on hepatic glucose output (Foretz et al., 2010).
Gluconeogenesis is an energetically costly anabolic process,
requiring six ATP equivalents per molecule of glucose synthe-
sized, and it seems likely that the metformin-induced increase
in AMP exerts amajor role in the flux control of hepatic gluconeo-
genesis by the drug. Indeed, AMP is a potent allosteric inhibitor
of fructose 1,6-bisphosphatase, a key enzyme in gluconeogen-
esis. Additionally, high AMP levels inhibit adenylate cyclase,
thereby reducing cyclic AMP (cAMP) formation in response to
glucagon and thus, fasting glucose levels (Miller et al., 2013).Cell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc. 955
Figure 1. Molecular Mechanisms of
Metformin-Induced Inhibition of Hepatic
Glucose Output
Metformin is transported into hepatocytes mainly
through OCT1 and partially inhibits mitochondrial
respiratory-chain complex 1, resulting in reduced
ATP levels and accumulation of AMP. Gluco-
neogenesis is reduced as a result of ATP deficit
limiting glucose synthesis, increased AMP levels
leading to reduced activity of the key gluco-
neogenic enzyme FBPase, inhibition of ad-
enylate cyclase and cAMP-PKA signaling, and
inhibition of mGPD contributing to altered redox
state and reduced conversion of glycerol to
glucose. Metformin-induced change in AMP/ATP
ratio also activates AMPK, which suppresses
lipid synthesis and exerts insulin sensitizing ef-
fects. Abbreviations: ACC, acetyl CoA carbox-
ylase; AMPK, AMP-activated protein kinase;
cAMP, cyclic AMP; complex 1, respiratory-chain
complex 1; DHAP, dihydroxyacetone phosphate;
FBPase, fructose-1,6-bisphosphatase; G3P,
glycerol-3-phosphate; cGPD, cytosolic glycer-
ophosphate dehydrogenase; mGPD, mitochon-
drial glycerophosphate dehydrogenase; OCT1,
organic transporter 1; PKA, protein kinase A.
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AMPK-independent regulatory points exist for direct AMP- and
ATP-mediated effects of metformin on gluconeogenesis (Fig-
ure 1). In addition, it was very recently reported that the reduction
in hepatic gluconeogenesis by metformin might result from a
direct inhibition of themitochondrial glycerophosphate dehydro-
genase (mGPD), identifying another putative mitochondrial
target of the drug (Madiraju et al., 2014). Inhibition of mGPD halts
the glycerophosphate shuttle, blocking gluconeogenesis from
glycerol and raising cytosolic NADH that feeds back on lactate
dehydrogenase and also impairs incorporation of lactate into
glucose.
Regulation of Lipid Metabolism
Another effect of metformin is to improve lipid metabolism by
reducing hepatic steatosis as demonstrated in rodent liver (Lin
et al., 2000; Woo et al., 2014) and also reported in a clinical study
(Marchesini et al., 2001). It was also recently reported that met-
formin exerts a beneficial effect on circulating lipids by lowering
plasma triglycerides, through a selective increase in VLDL-tri-
glyceride uptake and fatty acid oxidation in brown adipose tissue
(Geerling et al., 2014). Themetformin-induced reduction in tissue
lipid storage is consistent with an increase in both fatty acid
oxidation and inhibition of lipogenesis, presumably mediated
by AMPK activation (Geerling et al., 2014; Zang et al., 2004;
Zhou et al., 2001). Further support for a role of AMPK in the
mechanisms of metformin action on lipid metabolism was
recently provided in knockin mouse models in which ACC1
and ACC2 were rendered insensitive to AMPK phosphorylation
(Fullerton et al., 2013). These mice are refractory to the lipid-
lowering and insulin-sensitizing effects of metformin, showing
that metformin-induced reduction in blood glucose levels de-
pends on its ability to lower cellular fatty acid levels through
the AMPK-dependent phosphorylation of ACC. Thus, the inhibi-
tion of hepatic glucose production by metformin may be, at least
in certain conditions, secondary to the effects of the drug on
ACC. These observations offer a potential explanation for the956 Cell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc.lack of metformin action on blood glucose levels in liver-specific
LKB1-knockout mice fed on a high-fat diet (Shaw et al., 2005).
Indeed, impaired metformin-induced AMPK phosphorylation in
the absence of LKB1 would prevent ACC phosphorylation and
the ability of metformin to improve insulin sensitivity and lower
blood glucose. Therefore, metformin can acutely suppress he-
patic glucose output by acting on distinct metabolic pathways
via AMPK-independent and AMPK-dependent mechanisms in
the context of insulin resistance (Figure 1).
Metformin Action in Cardiovascular System
Metformin and Cardioprotection
Cardiovascular diseases are undoubtedly associated with T2D,
and ischemic heart disease is the main cause of death in the
T2D population (Grundy et al., 1999). The cardiovascular dys-
functions associated with T2D are macrovascular and microvas-
cular abnormalities including atherosclerosis of large arteries
and coronary atherosclerosis, which contributes to not only dia-
betes-related mortality and morbidity but also includes diabetic
cardiomyopathy, a specific heart muscle dysfunction that occurs
independently of coronary artery disease (Bugger and Abel,
2014). Although metformin is a first-line glucose-lowering phar-
macological agent, its use was historically contraindicated in pa-
tients with heart failure due to concerns regarding increased risk
of lactic acidosis. However, numerous studies revealed that met-
formin-associated lactic acidosis is minimal and that metformin
treatment clearly reduces mortality and morbidity of type 2 dia-
betic patients with cardiovascular diseases such as stable coro-
nary artery disease, acute coronary syndrome, and myocardial
infarction (Eurich et al., 2013; Masoudi et al., 2005). Currently,
clinical practice guidelines recommend using metformin as
first-line therapy in diabetic patients with heart failure (American
Diabetes Association, 2014). The UKPDS trial nicely demon-
strated that metformin was more effective than sulphonylurea
or insulin in patients allocated to intensive blood-glucose control
(1998). In this study, metformin significantly reduced all-cause
Figure 2. Main Putative Molecular
Mechanisms Involved in the
Cardioprotective Effects of Metformin
Animal and in vitro studies proposed a protective
action of metformin against several cardiovascular
diseases linked to T2D, including myocardial
infarction, hypertrophy, and diabetic cardiomy-
opathy, which lead to cardiac dysfunction that
could evolve to heart failure. The molecular
mechanisms involved in this protection are multi-
faceted, targeting endothelial, cardiomyocyte,
and fibroblast (dys)functions. More details are
given in the text. Abbreviations: AGEs, advanced
glycation end-products; AMPK, AMP-activated
protein kinase; eEF2K, eukaryotic elongation
factor 2 kinase; eNOS, endothelial nitric oxide
synthase; ER, endoplasmic reticulum; ICAM-1,
intercellular adhesion molecule-1; MAPK,
mitogen-activated protein kinase; MnSOD,
Manganese superoxide dismutase; mPTP, mito-
chondrial permeability transition pore; mTOR,
mammalian target of rapamycin; NFAT, calci-
neurin-nuclear factor of activated T cells; NOX,
NADPH oxidase; PGC-1a, peroxisome pro-
liferator-activated receptor-gamma coactivator-
1alpha; ROS, reactive oxygen species; TGF-b,
transforming growth factor-b; VCAM-1, vascular
cell adhesion molecule-1.
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tively with a significant reduction in myocardial infarction events,
which persisted after a 10-year follow-up (Holman et al., 2008).
Numerous recent studies have confirmed the UKPDS conclu-
sions. In these studies, metformin use was associated with bet-
ter short- and/or long-term prognosis than other antidiabetic
treatments in diabetic patients with acute coronary syndrome
(Hong et al., 2013) or chronic heart failure (Eurich et al., 2013).
However, it has to be noted that the benefit obtainedwithmetfor-
min in comparison to the other glucose-lowering agents is gener-
ally quite modest. Importantly, the use of metformin in nondia-
betic patients suffering from coronary heart disease was not
associated with any beneficial effects (Lexis et al., 2014; Preiss
et al., 2014). Several meta-analyses have been recently per-
formed (Boussageon et al., 2012; Eurich et al., 2013; Lamanna
et al., 2011). Their inclusion criteria (only population at low risk
of mortality; including or not patients with heart failure; including
or not nondiabetic patients) and their conclusions slightly differ.
The first concludes that metformin monotherapy improves sur-
vival whereas concomitant utilization with sulphonylurea was
associated with reduced survival (Lamanna et al., 2011). In the
second, the effectiveness of metformin to avoid death or cardio-
vascular events is not established by existing studies for the sec-
ond meta-analysis (Boussageon et al., 2012). Finally, the more
recent meta-analysis indicates that metformin treatment is asso-
ciated with reduced mortality compared with controls and is at
least as safe as other glucose-lowering agents in diabetic pa-
tients with heart failure (Eurich et al., 2013). Future clinical trials
are clearly necessary to definitively conclude about the safety
and cardioprotective effects of metformin treatment.
Metformin in Hypertension and Atherogenesis
The mechanisms involved in the beneficial cardiovascular ef-
fects of metformin in diabetic patients are not fully understood.A plausible explanation is the systemic antihyperglycemic effect
of the drug, whereby lowered gluconeogenesis decreases
glucose levels and secondarily reduces insulin levels. However,
several other molecular mechanisms directly targeting the car-
diovascular system have been suggested by animal studies to
participate in the benefits of metformin (Figure 2). A large part
of these effects appears to bemediated by AMPK. The activation
of AMPK by metformin-induced energy stress is relevant to the
vascular system, which is known to be altered in diabetes by
endothelial dysfunction and atherogenesis. Atherogenesis is
accompanied by an impairment of endothelium-dependent
relaxation, increased ROS production, and reduced nitric oxide
(NO) bioavailability, mediating proinflammatory and prothrom-
botic mechanisms including platelet aggregation and leukocyte
adhesion to the wall. Several cellular and animal studies have
evaluated the potential antiatherogenic action of metformin
and AMPK activation. Metformin has been shown to inhibit
high glucose-dependent ROS overproduction in aortic endothe-
lial cells and its consequent endothelial dysfunction (Detaille
et al., 2005; Ouslimani et al., 2005). The decrease in ROS
production is mediated by a double mechanism involving a
reduction in NADPH oxidase activity and an inhibition of the res-
piratory-chain complex 1. Two more recent studies proposed
that AMPK mediates this metformin-induced NADPH oxidase
inactivation reducing cytoplasmic ROS production (Batchuluun
et al., 2014; Bhatt et al., 2013). In parallel, Kukidome and
colleagues showed that AMPK activation reduces the hypergly-
cemia-mediated mitochondrial ROS overproduction via the in-
duction of manganese superoxide dismutase and the promotion
of peroxisome proliferator-activated receptor-gamma coactiva-
tor-1alpha (PGC-1a)-dependent mitochondrial biogenesis in hu-
man umbilical vein endothelial cells (Kukidome et al., 2006).
AMPK activation is also known to induce endothelial NOCell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc. 957
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line with this action, it has been recently shown that metformin
restores endothelial function through the inhibition of endo-
plasmic reticulum (ER) stress and oxidative stress and via the in-
crease in NO bioavailability in obese diabetic mice, these effects
being mediated by the AMPK/peroxisome proliferator-activated
receptor d pathway (Cheang et al., 2014). In addition, metformin
targets advanced glycation end-products (AGEs), which are sig-
nificant contributors of complications linked to diabetes. Indeed,
metformin, independently of its antihyperglycemic property, is
able to reduce AGEs synthesis and the expression of their spe-
cific cell receptor called RAGE in endothelial cells (Ouslimani
et al., 2007). Finally, metformin treatment of patient with T2D
was associated with a decrease in the level of the soluble inter-
cellular adhesion molecule-1 (ICAM-1) and the soluble vascular
cell-adhesion molecule-1 (VCAM-1), both being directly corre-
lated to increase in cardiovascular events in such population
(De Jager et al., 2005). Interestingly, as for AGEs, this decrease
in ICAM-1 and VCAM-1 level was independent of the antihyper-
glycemic action of the drug.
Metformin in Myocardial Injury
The protective action of metformin also occurs at the myocar-
dium and cardiomyocyte levels. Several ex vivo experiments
using perfused heart protocols revealed a protective action of
metformin during an ischemic episode. In a working-heart perfu-
sion model where metformin is administered before a mild
ischemic episode, the antidiabetic drug improved rat cardiac
functional postischemic recovery (Legtenberg et al., 2002). It
has been also shown that metformin given at the time of reper-
fusion reduced myocardial infarct size in both nondiabetic and
diabetic hearts (Bhamra et al., 2008; Paiva et al., 2009). In these
two last studies, the protective action of metformin was associ-
ated with a PI3K-mediated inhibition of the mitochondrial
permeability transition pore opening and with increased intra-
cellular formation of adenosine. However, the same group also
showed that chronic metformin treatment of diabetic rats aug-
ments their myocardial resistance to ischemia-reperfusion injury
via a pathway involving AMPK activation and PGC-1a (Whitting-
ton et al., 2013). Similar results have been obtained using in vivo
models of myocardial infarction. In mice subjected to perma-
nent left coronary artery occlusion or to 1 hr left coronary artery
occlusion followed by reperfusion, 4 weeks metformin treatment
improved survival and preserved left ventricular dimensions and
left ventricular ejection fraction (Gundewar et al., 2009). These
effects were concomitant to AMPK and eNOS activation, to in-
crease in PGC-1a expression and disappeared in mice lacking
AMPK or eNOS. In a similar study, Yin and colleagues de-
monstrated that metformin treatment increases AMPK activity,
improves cardiac function and reduces infarct size after a
myocardial infarction in rats (Yin et al., 2011). This protective ac-
tion of metformin was also established in a dog model of heart
failure (Sasaki et al., 2009). The authors nicely showed that other
AMPK activators, such as 5-aminoimidazole-4-carboxamide
1-b-D-ribofuranoside (AICAr), have the same effect than metfor-
min, suggesting a role of this protein kinase. In cardiomyocytes,
metformin reduced apoptosis by increasing antiapoptotic pro-
teins and attenuating the production of pro-apoptotic proteins
(Yeh et al., 2010). These effects correlate with AMPK activation
and can be reproduced by AICAr (Yeh et al., 2010). Metformin958 Cell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc.and AMPK also influence autophagy, which is known to be dys-
regulated in diabetic cardiomyopathy and heart failure. Indeed,
metformin is able to restore impaired autophagy via the dissoci-
ation of Bcl-2 from Beclin 1 in diabetic wild-type mice but not in
cardiac-specific AMPK-dominant-negative transgenic diabetic
mice (He et al., 2013; Xie et al., 2011).
Metformin in Cardiac Hypertrophy
Left ventricular hypertrophy is common among patients with
T2D, who commonly have chronic hypertension. AMPK is a
known inhibitor of cardiac hypertrophy via the negative regu-
lation of protein synthesis (via mTOR inhibition) and of gene
transcription includingmitogen-activated protein kinase and cal-
cineurin-nuclear factor of activated T cells pathways (Horman
et al., 2012). In agreement with the antihypertrophic action of
AMPK, metformin inhibits cardiac hypertrophy in a rat model of
pressure overload (transverse aortic constriction) (Zhang et al.,
2011). A very recent publication has reported thatmetformin pro-
tects against transverse aortic constriction-mediated cardiac
hypertrophy independently of AMPK (Xu et al., 2014).
Metformin in Diabetic Cardiomyopathy
A healthy human heart produces around 5 to 6 kg of ATP each
day to sustain its function, representing 20 times its own weight
(Horman et al., 2012). This ATP is generated via the mitochon-
drial oxidation of fatty acids (for 70%) and glucose/pyruvate
(for 30%). Fatty acids are preferred substrates because their
oxidation inhibits glucose catabolism via the Randle cycle. How-
ever, in the postprandial state, insulin favors glucose utilization
by promoting glucose uptake and glycolysis and inhibiting fatty
acid oxidation. Currently, it is commonly accepted that this
metabolic flexibility is essential for the maintenance of heart
function. On the other hand, the metabolic inflexibility of diabetic
hearts, which are insulin resistant and almost exclusively use
fatty acids as source of energy, participates in the development
of the diabetic cardiomyopathy (Bugger and Abel, 2014). Thus,
therapies that promote glucose metabolism and normalize
insulin sensitivity may reduce cardiac complications linked to
diabetes. Metformin and AMPK are potential therapeutic candi-
dates. Indeed, AMPK activation by metformin or other activators
is able to stimulate cardiac glucose uptake and glycolysis inde-
pendently of insulin, bypassing insulin resistance in insulin-resis-
tant cardiomyocytes (Bertrand et al., 2006; Ginion et al., 2011).
Even more interestingly, increase in AMPK activity by the same
activators restored insulin sensitivity of insulin-resistant cardio-
myocytes by a mechanism that still needs to be identified
(Bertrand et al., 2006; Ginion et al., 2011). The concentration of
metformin used in these acute (few hours) studies was, however,
higher than those used in diabetic patients. We can postulate
that lower concentrations of metformin could play similar role
when utilized during longer time of exposure. In relation to the
problematic of the effective dose of metformin in the heart, a
new specific activator of AMPK (A-769662) has been recently
shown to increase metformin sensitivity independently of the
AMP/ATP ratio (Timmermans et al., 2014). Such compound
might be useful clinically to increase metformin cardiac sen-
sitivity.
On the other hand, similarly to the situation found in endothelial
cells (Detaille et al., 2005; Ouslimani et al., 2005), hyperglycemia
induced NADPH oxidase-mediated ROS production and cell
death in cardiomyocytes (Balteau et al., 2011). It is tempting to
Figure 3. Proposed Mechanisms by which
Biguanides May Influence Cancer Biology
These mechanisms may be indirect, where the
drug does not interact with the cancer cells but
rather alters the endocrine-metabolic milieu of the
host in a way that may influence cancers. Indirect
effects include but are not confined to suppression
of gluconeogenesis and decreased systemic
glucose and insulin levels. The insulin-lowering
effect of metformin is used as an example; other
indirect mechanisms have been proposed. Direct
interactions between biguanides and cancers are
supported by recent experimental data and occur
when drug exposure is adequate to induce ener-
getic stress in cancer cells. There is uncertainty if
conventional antidiabetic doses of metformin are
sufficient to accomplish this. Genetic character-
istics of a cancer likely influence not only the
extent to which biguanides accumulate but also its
ability to deal with energetic stress, and thus the
degree of therapeutic benefit. Abbreviations: GI,
gastrointestinal; LKB1, liver kinase B1; OXPHOS,
oxidative phosphorylation.
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reduce this ROS production and to increase cardiomyocyte sur-
vival under hyperglycemic condition as demonstrated in the
endothelium (Batchuluun et al., 2014; Bhatt et al., 2013). In
agreement with this hypothesis, it has been recently shown
that AMPK activation by A-769662, the metformin analog phen-
formin, or the new antidiabetic drug GLP-1 limited glucotoxicity
in adult cardiomyocytes (Balteau et al., 2014). The mechanism
proposed in this study is the AMPK-dependent suppression of
the hyperglycemia-mediated ROS production via the inhibition
of the NADPH oxidase NOX2.
Metformin in Cardiac Fibrosis
Cardiac fibrosis is another element of diabetic cardiomyopathy
and more generally heart failure. Interestingly, metformin is
able to attenuate fibrosis in a canine model of heart failure, pre-
sumably via AMPK activation and its inhibitory action on trans-
forming growth factor-b expression (Sasaki et al., 2009). Similar
results were obtained in mice subjected to left ventricular pres-
sure overload by transverse aortic constriction even if, in this
case, AMPK did not seem to be involved (Xiao et al., 2010). In
other studies, it has been established that metformin inhibits my-
ofibroblast differentiation by suppressing ROS generation via the
inhibition of the NADPH oxidase pathway (Bai et al., 2013),
AMPK probably mediating this effect. Of note, a genetic link be-
tween AMPK and cardiac fibrosis has been recently demon-
strated in a myocardial infarction mouse model (Noppe et al.,
2014).
Antineoplastic Actions of Metformin
Pharmaco-Epidemiology
Pharmaco-epidemiologic evidence has played a major role in
generating the hypothesis that metformin has utility in cancer
prevention and/or treatment. A seminal report published in
2005 (Evans et al., 2005) presented evidence that diabetics
treated with metformin had a substantially lower cancer burdenCell Metabolism 20, Dthan diabetics treated with other agents,
and many other studies reached similar
conclusions (Gandini et al., 2014). How-ever, while results of certain studies are encouraging, there are
contradictions in the available data, and the hypothesis remains
controversial (Tsilidis et al., 2014). Obviously, the populations
under study were type 2 diabetic patients, and the conclusions
may not be applicable to nondiabetic subjects, even if the con-
clusions were validated for diabetics. More importantly, all these
studies are based on retrospective reviews of medical records
and are subject to a variety of potential biases (Suissa and Azou-
lay, 2014). On the other hand, some recent reports are consistent
with the earlier pharmaco-epidemiologic data that provided evi-
dence for reduced cancer burden among users ofmetformin. Ex-
amples include a study of multiple myeloma outcomes (Wu et al.,
2014), one of prostate cancer risk based on the Danish cancer
registry (Preston et al., 2014), and one regarding prostate cancer
prognosis (Margel et al., 2013). Thus, pharmaco-epidemiologic
data have played an important role in generating the hypothesis
that metformin may be useful in cancer prevention or treatment
but have not been consistent in supporting this concept.
Indirect Effects of Metformin on Cancer
The proposed mechanisms of action of metformin relevant to
oncology can be divided into two broad, non-mutually exclusive
categories: effects on the host that indirectly influence the can-
cer and direct effects on cancer cells (Pollak, 2012b) (Figure 3).
As noted earlier in this review, direct actions of metformin on
the liver inhibit hepatic glucose production, resulting in systemic
metabolic and endocrine effects that may influence cancer
biology. The most obvious candidate change of oncologic rele-
vance is the reduction of hyperinsulinemia, given prior evidence
that high insulin levels can stimulate proliferation of a subset of
common cancers (Pollak, 2012a). Importantly, however, the
magnitude of metformin-induced decline in insulin levels is
greater in type 2 diabetics than in metabolically normal subjects,
and it is not clear if metformin-induced changes in plasma insulin
levels, particularly in nondiabetics, are sufficient to perturb tumor
biology. Nevertheless, there is evidence from a murine modelecember 2, 2014 ª2014 Elsevier Inc. 959
Cell Metabolism
Reviewthat metformin administration is more effective with respect to
tumor growth inhibition when diet-induced obesity and hyperin-
sulinemia are present, and it is associated with decreased acti-
vation of insulin receptors of cancer xenografts (Algire et al.,
2011). Levels of various adipokines relevant to cancer biology
are also influenced by metformin in models, but further clinical
data in this area are required. Also, a few studies have suggested
immunological or anti-inflammatory actions of metformin (Moi-
seeva et al., 2013; Pearce et al., 2009) relevant to oncology,
but there are to date no clinical data to support or refute these
observations. Thus, the role of ‘‘indirect’’ actions of metformin
remains an active research topic.
Direct Effects of Metformin on Cancer
Dozens of in vivo and in vitro studies have shown direct anti-
neoplastic activity of biguanides in model systems, but most
of these have neither provided mechanistic details nor consid-
ered dose-response issues relevant to clinical applications
(Pollak, 2012b; Viollet et al., 2012). One of these (Huang
et al., 2008) provided evidence that AMPK activation is impor-
tant in the action of biguanides by showing that the direct
AMPK activator A-769662 (which does not inhibit OXPHOS)
has in vivo antineoplastic activity. Other observations suggest
the relevance of inhibition of respiratory-chain complex 1 within
tumors underlies the therapeutic effect of metformin in vivo un-
der conditions where dosing is adequate: a key finding was that
tumor growth inhibition by metformin occurs under control con-
ditions, but not when the tumor model is engineered to express
the yeast metformin-resistant Saccharomyces cerevisiae NADH
dehydrogenase NDI1 protein (Birsoy et al., 2014; Wheaton
et al., 2014).
Alterations in cellular metabolism in a manner that is influ-
enced by mutations in exposed cancer cells are important con-
sequences of metformin-induced reduction of OXPHOS (Buzzai
et al., 2007). This suggests the possibility of rational drug combi-
nations (Ben Sahra et al., 2010). Particularly interesting work has
provided a metabolic rationale for combining biguanides with
small molecule drugs that inhibit oncogenic kinases that drive
glycolysis (Pollak, 2013b). These studies support the possibility
that cancer cells have a requirement to increase OXPHOS, at
least transiently, to compensate for the decreased glycolysis
that arises as a consequence of oncogenic kinase inhibition. In
the presence of biguanides, this compensatory increase is atten-
uated, resulting in enhanced antineoplastic activity of the kinase
inhibitor (Haq et al., 2013). Mutation of isocitrate dehydroge-
nase-1 (IDH-1) is an important topic in cancer metabolism, and
there is preclinical evidence justifying study of the combination
of a biguanide and inhibitors of mutated IDH-1 (Grassian et al.,
2014). There is also evidence of a benefit of combining bigua-
nides with conventional chemotherapy, radiotherapy, and hor-
monal therapies (Pollak, 2012b).
An early finding supporting a direct action of metformin
on cancer cells was the observation that the drug was growth
inhibitory in vitro in a manner that was associated with AMPK
activation and mTOR inhibition as a consequence of metfor-
min-induced energetic stress (Zakikhani et al., 2006). Further
work in this direction showed that genetic ablation of the a1 cat-
alytic subunit of AMPK acceleratesMyc-induced lymphomagen-
esis, consistent with the observation that AMPK activation not
only downregulates mTOR but also suppresses the excess960 Cell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc.aerobic glycolysis (Warburg effect) characteristic of most trans-
formed cells (Faubert et al., 2013). This line of investigation sug-
gests a tumor suppressor role for AMPK.
However, it is now recognized that AMPK activation under
conditions of energetic stress can improve cell survival (Jeon
et al., 2012) by tuning cellular energy metabolism to reduce en-
ergy consumption, in keeping with the evolutionary role of
AMPK in adjusting metabolism to cope with low nutrient supply.
Thus, it remains to be determined if the antiproliferative but pro-
survival consequences of AMPK activation in cancer cells, either
due to the inhibition of OXPHOS by metformin or the direct acti-
vation by specific pharmacological activators, will be of clinical
benefit.
Consideration of the consequences of biguanide-induced en-
ergetic stress in cancer cells defective in AMPK activation is of
particular interest. Xenograft (Algire et al., 2011) and transgenic
(Shackelford et al., 2013) models have shown that cancers
with loss of function of LKB1 are hypersensitive to biguanides.
This observation is consistent with the notion that activation of
AMPK, while associated with reduction in proliferation, actually
mitigates energetic stress induced bymetformin by reducing en-
ergy consumption, thereby favoring cell survival. Cancer cells
functionally deficient in AMPK, in contrast, will be less likely to
reduce energy consumption in face of biguanide-induced reduc-
tion in ATP generation and are therefore more likely to experi-
ence a lethal energetic crisis. This scenario is attractive because
it implies a favorable therapeutic index (a greater effect on the
cancer than the normal host tissues), as AMPK-defective can-
cers would be more sensitive to biguanides than normal tissues
that retain a functional AMPK signaling system. This situation
may be relevant to a sizable proportion of human cancers: for
example, more than a third of non-small cell lung cancers are re-
ported to be LKB1 defective. Cancers with mutations in genes
encoding respiratory-chain complex 1 components have also
been shown to be hypersensitive to biguanides (Birsoy et al.,
2014).
Collectively, preclinical studies raise enthusiasm for clinical
trials of metformin in a manner that is less controversial than
the pharmaco-epidemiologic rationale. However, it is clear
that precise mechanisms have not been defined, and it is im-
portant to point out that in order for metformin to have a direct
antineoplastic effect, an adequate drug concentration must be
achieved in neoplastic tissue. This concentration will be deter-
mined not only by the plasma level, which is related to the
administered dose and to pharmacokinetic variables, but also
to cellular uptake in cancer cells that may vary with respect to
expression of OCT1 and other relevant transporters. The serum
levels of metformin achieved in diabetic patients and in many
in vivo models (as reviewed above) are in the micromolar range,
while growth inhibition in vitro is usually observed at millimolar
concentrations. Thus, an overarching research question is
what metformin concentrations are achieved in neoplastic tis-
sue of patients receiving conventional antidiabetic doses of
metformin. Even before consideration of tumor biology, there
may well be heterogeneity between cancer patients with
respect to direct actions of metformin that arise as a con-
sequence of whole-organism and cellular pharmacokinetic fac-
tors. Imprecision regarding achieved drug levels in target
tissues in preclinical models that demonstrate antineoplastic
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uncertain if the laboratory data should be used to support clin-
ical trials of conventional antidiabetic doses of metformin or
clinical trials of more aggressive and novel methods of bigua-
nide administration designed to maximize tumor drug concen-
tration.
Clinical Advances and Outlook
Whilemany clinical trials are ongoing, few actual clinical outcome
results have been reported to date. However, there have been
many publications of pilot studies that refer to surrogate end-
points such as changes in tumor proliferation rate between serial
tumor biopsies obtained from patients prior to and during
metformin exposure.Many of these have shown encouraging de-
creases in proliferation in breast, prostate, and endometrial can-
cers (Pollak, 2012b; Viollet et al., 2012), but overall results have
been difficult to interpret because the magnitude of declines is
in many cases smaller than those associated with currently
approved treatments and because in some studies declines are
confined to subsets of patients. It should be noted that the design
of ongoing randomized clinical trialsmay not address someof the
specific contexts suggested to be of high interest by preclinical
work performed only after the trials were designed, such as stra-
tegic combinations of biguanides with tyrosine kinase inhibitors
(Pollak, 2013b) or selective use of biguanides for tumors with res-
piratory-chain complex 1 mutations (Birsoy et al., 2014).
Anecdotal clinical evidence of stimulation of glucose uptake
by intestinal mucosa bymetformin has been presented in the nu-
clearmedicine literature (Gontier et al., 2008). While from a radio-
logic perspective this was reported as a bothersome artifact,
from a physiologic perspective the data may represent phar-
macodynamic evidence of biguanide-induced inhibition of
OXPHOS in intestinal mucosa, leading to energetic stress and
a compensatory increase in glycolysis, resulting in the observed
increase in glucose uptake. This may take place preferentially in
bowel as compared to other tissues because of the high luminal
concentration of metformin following oral administration, em-
phasizing the importance of pharmacokinetic factors in deter-
mining tissues where direct biguanide actions are likely to occur.
These data are correlated with greater reductions of proliferation
rate by metformin in colon (Pollak, 2013a) than in most other tis-
sues examined, and reduced aberrant crypt foci in patients
(Hosono et al., 2010), thus raising the possibility of specific appli-
cations for metformin in colorectal cancer prevention.
Ongoing research comprises two broad areas. One examines
the hypothesis that metformin, when administered in the manner
used for diabetes therapy, has utility for cancer prevention or
treatment. There has been relatively little effort to address this
possibility in a quantitative fashion in preclinical model systems
because it is difficult to accurately simulate human pharmacoki-
netics following oral dosing in rodents, and because there has
been enthusiasm among physicians to proceed directly to hu-
man studies (Pollak, 2014). Thus, there are more than 200
oncology clinical trials involving metformin in progress. Another
research area, which has not yet led to clinical trials, involves
optimization of biguanide pharmacokinetics to maximize expo-
sure of neoplastic tissue. This work is based on one hand on
the attractive laboratory data related to the ‘‘direct’’ mechanism
of action and on the other hand on concern that conventional
antidiabetic dosing may be inadequate for the desired effects.Relative to metformin, phenformin or novel biguanides (Narise
et al., 2014) may have reduced requirements for cell surface
transporters to enter cancer cells or other desirable pharmacoki-
netic properties. This has been clearly evidenced in rat hepa-
toma cells H4IIE, where quinidine, a competitive OCT1 inhibitor,
completely blocked AMPK activation by metformin, while AMPK
activation by phenformin and galegine was not affected (Hawley
et al., 2010). Metformin may have very different effects if given
parentally rather than orally. However, while such approaches
may have advantages, they also may be associated with unac-
ceptable toxicity, so that conventional preclinical work leading
to phase I safety and dose-finding clinical trials would be
required as a first step.
Conclusion and Therapeutic Perspectives
After more than 50 years of clinical experience, the utility of met-
formin in the control of hyperglycemia in T2D has been well
established. The safety of metformin differentiated it from phen-
formin and buformin, which were withdrawn in most countries
due to a higher risk incidence of lactic acidosis. The favorable
risk/benefit profile of metformin has made it one of the most
widely prescribed drugs in the world. Clinically, metformin exerts
its antihyperglycemic effect mostly through the inhibition of he-
patic gluconeogenesis. Its primary site of action is the mitochon-
dria via its mild and specific inhibition of the respiratory-chain
complex 1, thereby lowering energy charge and ultimately lead-
ing to a reduction in hepatic glucose output. Although the energy
sensor AMPK is activated by a decrease in the cellular energy
charge, it appears to be dispensable for the direct inhibitory
effect of metformin on hepatic gluconeogenesis but still may
indirectly inhibit by restoring hepatic insulin sensitivity. This is
consistent with the role of AMPK in the lipid-lowering effects
and improvements in insulin sensitivity by metformin in the liver.
Recent advances revealed a new molecular target in the mito-
chondria with the direct inhibition of mGPD, resulting in altered
cellular redox state and limiting lactate and glycerol contribution
to hepatic gluconeogenesis.
The evidence presented in this review suggests that metformin
may have clinical value in the treatment of cardiovascular com-
plications associated with T2D by exerting a variety of cellular
actions in different tissues and cell types. Chronic metformin
treatment of patients leads to a basal state of cardioprotection,
thereby potentially limiting the occurrence of myocardial infarc-
tion, heart failure, diabetic cardiomyopathy, and cardiac hyper-
trophy.Multiplemolecularmechanismswere proposed, including
reduction of ER stress, oxidative stress, apoptosis, and protein
synthesis, as well as insulin resistance in endothelial cells, cardi-
omyocytes, and cardiac fibroblasts through AMPK-dependent
and AMPK-independent pathways.
Some studies have raised the possibility that metformin may
also be effective in providing protection against cancer. The
concept of ‘‘repurposing’’ metformin for cancer prevention or
treatment is appealing (Pollak, 2014), as the drug is inexpensive
and well tolerated relative to commonly used antineoplastic
agents. The original and most optimistic hypothesis, that this
drug at conventional antidiabetic doses is useful for a wide vari-
ety of indications in oncology, was based in part on pharmaco-
epidemiologic data that are now considered controversial. As
most experimental evidence for antineoplastic activity ofCell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc. 961
Table 1. Examples of Challenges in Biguanide Research
Elucidate the precise mechanism(s) by which metformin interacts with and inhibits the mitochondrial respiratory-chain complex 1
Clarify the effect of metformin on tissue-specific regulation of mitochondrial biogenesis and its subsequent impact on cellular energy homeostasis
Clarify if metformin actually acts as an ‘‘insulin sensitizer’’ in vivo or if the reduction of insulin level associated with use of the drug is completely
accounted for by decrease in glucose secondary to decrease gluconeogenesis
Define mechanisms that limit duration of efficacy of metformin in treatment of T2D
Clarify why cardiac benefits of metformin are greater in diabetics than nondiabetics
Provide clinical evidence for or against clinical antineoplastic action of metformin in diabetic and nondiabetic cancer patients
Define optimum dosing of biguanides for cancer treatment in diabetic and nondiabetic patients, and establish if phenformin or novel biguanides
offer advantages for cancer treatment
Delineate the role of AMPK in metformin action in different tissues and different disease states
Design and evaluate rational combinations of metformin with other pharmacological agents for various indications
Understand the genetic influences on efficacy of metformin for various indications and move toward personalized medicine to optimize therapies
Are recently described actions of metformin on the intestinal microbiome (Cabreiro et al., 2013) relevant to any of the clinical effects of the drug?
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than those in serum of metformin-treated diabetics, the use of
novel metformin dosing strategies, including intravenous rather
than oral administration, as well as the use of phenformin or
novel biguanides designed to have pharmacokinetic character-
istics optimized for oncologic indications may be worthwhile.
Furthermore, preclinical studies have identified not only
rational drug combinations involving biguanides that deserve
evaluation but also specific tumor characteristics, such as mu-
tations of STK11/LKB1, that may be associated with biguanide
sensitivity. Therefore, even if the first generation of metformin
trials for cancer treatment is disappointing, there will be inter-
esting questions to address in subsequent studies. On the
other hand, demonstration of clinical benefit of any of the
ongoing trials would represent an important example of pro-
ductive ‘‘repurposing’’ research and lead to efforts to build on
that success.
Among clinicians, metformin is regarded as a widely used and
‘‘mature’’ generic drugwith awell-established and important role
in treatment of T2D, for which there is a limited research agenda
remaining. However, as reviewed here, from a mechanistic per-
spective, there are many important unanswered questions
(Table 1) and a recognition that biguanides have unique thera-
peutic properties arising from their effects on cellular energy
metabolism. It is possible that further understanding of the
mechanistic aspects of biguanide pharmacology will result in ad-
vances in treatment not only of diabetes but also in cardiovascu-
lar and neoplastic diseases.
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